TELOMIR PHARMACEUTICAL

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

17 6月 2024 15:10:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

30 5月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

16 4月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

02 4月 2024 07:30:00 条件 Nasdaq GlobeNewswire

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

29 3月 2024 15:44:21 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

26 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

22 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

14 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

07 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

05 3月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

13 2月 2024 15:05:00 条件 Nasdaq GlobeNewswire